22 miljarder – så mycket kostar det att utveckla ett nytt läkemedel

Den genomsnittliga kostnaden för Big Pharma att ta ett läkemedel hela vägen från upptäckt till lansering var i fjol 2,23 miljarder dollar, motsvarande en bra bi...

Mercodia AB

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Trump in new push to lower drug prices

U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in othe...

USA-besked får Lundabolag att backa på börsen – ”Beslutet från FDA är beklagligt”

Brister hos en kontraktstillverkare riskerar att försena ett eventuellt godkännande av Camurus läkemedelskandidat mot en sällsynt hormonsjukdom i USA. Beskedet ...

Vaccine skeptic David Geier to lead study on link to autism

The American government is to launch a study on whether vaccines cause autism – and has appointed a well-known vaccine skeptic to lead the analysis.

”The importance of stratification in a statistician’s August kitchen”

Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.

WuXi AppTec, UK Ltd

Quality Assurance for the Highest Medical Standards

Metrology Solutions for Medical Components.

The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...

Quotient Sciences Limited

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Lonza

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...

Virology professor on the threat from X: ”The next pandemic could be worse“

The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", r...

Stockholm and Uppsala jointly form a life science cluster

Stockholm and Uppsala are strengthening cooperation in medical research and biotech.

Innovative start-up helps doctors, scientists and industry balance coagulation risks

in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial fo...

It couldn’t be simpler

AI-assisted ZEISS Solution inspects implant coatings automatically.

Metabolon

Revealing the secrets of a part

CT inspection in automation technology at Festo.

Ingrid Lönnstedt: Demystification of the power of a scientific study

”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...

Introducing ZEISS arivis Pro 4.2

Your solution for advanced image analysis and visualization.

Improved processes and more

Discover the full potential and benefits.

Säkerhetsbrist i svensk programvara för bröstcancerscreening – kvinna avled

En brist i Sectras programvara ledde till att en kvinna med bröstcancer fick ett felaktigt besked. Hon avled senare. Programmet används i 20 av 21 regioner i Sv...